Blog

T cells

New FDA guidance: cell therapies and patient identifiers

When the US Food and Drug Administration (FDA) recently made two draft guidance documents for the cell and gene therapies available for comment, the Vineti team was quick to scan for one three-letter phrase that is core to our mission – COI.

Read More
April 20, 2022

sedApta Group and Vineti partner to develop integrated digital supply chain and manufacturing solution for cell and gene therapies

The sedApta Group, a global software provider specialized in innovative IT solutions for digital Supply Chain and Smart Manufacturing, and Vineti, the provider of the…

April 7, 2022

Cell and gene therapies: the necessity of a purpose-built platform

Given the wide array of CRMs and other digital systems already serving healthcare and biopharma, that reality might sound like overkill. But after more than…

March 25, 2022

Gene therapies – simpler doesn’t mean simple

Cell and gene therapies are produced and delivered via the most complex workflows in the history of medicine. Among those workflows, though, there’s a range…

March 23, 2022

Vineti secures new patent from USPTO for individualized medicine platform

SAN FRANCISCO, March ##, 2022 (GLOBE NEWSWIRE) – Vineti, Inc., the provider of the leading digital platform of record for cell and gene therapies, today…

March 18, 2022

Cell and gene therapies – new treatments, new value

At the recent Gene Therapy for Rare Disorders conference in Boston, I had the opportunity to discuss thoughts on value with an audience dedicated to…

March 4, 2022

Vineti Appoints Ann Klein as Chief Executive Officer

Vineti, Inc., the provider of the leading digital platform of record for personalized therapeutics, today announced the successful completion of its Service Organization Control (SOC®)…

February 2, 2022

Vineti’s Personalized Therapy Management® (PTM) solution meets rigorous standards: Service Organization Control (SOC®) 2 Type II compliance audit

Vineti, developer of the leading digital platform of record for personalized therapeutics, today announced a new Integration Suite as a cornerstone of its Personalized Therapy…

January 27, 2022

Vineti achieves SOC2 Type II compliance

Vineti, Inc., the provider of the leading digital platform of record for personalized therapeutics, today announced the successful completion of its Service Organization Control (SOC®)…

January 10, 2022

Vineti introduces new PTM® Integration Suite: purpose-built connectivity and interoperability for cell and gene therapies

Vineti, developer of the leading digital platform of record for personalized therapeutics, today announced a new Integration Suite as a cornerstone of its Personalized Therapy…

January 6, 2022

Why an integrated, digital cell and gene therapy (CGT) ecosystem protects patients and their privacy

Cell and gene therapies (CGTs) are modern, technologically advanced therapies that rely on a complex value chain for manufacturing and patient treatment. Patients are at…

December 22, 2021

Why CGT 3.0 success depends on interoperability

The cutting edge therapies of CGT 3.0 require modern operations. That means far more than just stand-alone digital systems and select integrations — it means…

December 16, 2021

How integrated digital systems solve key challenges with cell and gene therapies (CGTs)

One patient. One cell therapy. Ten or more distinct digital systems.
That’s often the number of heterogeneous digital systems across care sites, manufacturers, and…